+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Beta Lactam & Beta Lactamase Inhibitors Market Research Report by Drug Class (Carbapenem, Cephalosporins, and Monobactam), Disease, Route of Administration, Region - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - Global Forecast 2023-2030

  • PDF Icon

    Report

  • 247 Pages
  • January 2023
  • Region: Global
  • 360iResearch™
  • ID: 5715533
UP TO OFF until Mar 31st 2023
The Global Beta Lactam & Beta Lactamase Inhibitors Market size was estimated at USD 32.99 billion in 2022, USD 36.31 billion in 2023, and is projected to grow at a CAGR of 10.52% to reach USD 73.47 billion by 2030.

Cumulative Impact of COVID-19:

COVID-19 is an unprecedented global public health emergency that affected almost every industry, and the long-term impacts are projected to reflect on the growth of various end-use industries during the forecast period. This ongoing research amplifies the research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19, considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The dedicated section in the report uncovers a detailed analysis of the impact of COVID-19 and its subsequent variant outbreaks on demand, supply, price, and vendor uptake and provides recommendations for sustainable outcomes. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the Global Beta Lactam & Beta Lactamase Inhibitors Market.

Cumulative Impact of Russia-Ukraine Conflict:

The publisher continuously monitors and update reports considering unceasing political and economic uncertainty due to the Russia-Ukraine Conflict. Negative impacts are globally foreseen, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected people’s lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on Ukraine and reverberate harsh long-term effects on Russia. The report uncovers the implications for demand-supply balances, pressure on pricing variants, impact on import/export and trading, and short-term recommendations to the Global Beta Lactam & Beta Lactamase Inhibitors Market considering the current update on the conflict and its global responses.

Cumulative Impact of High Inflation:

The high inflation in developed economies globally has resulted in an overall price surge over the past two years. The cumulatively eroding overall purchasing power is expected to impact developing economies significantly and is considered helpful in numerous ways. The report uncovers the effect of high inflation on the long-term performance of the global economy and provides details on fiscal policies measuring and reducing its short-term impacts on demand/supply, cash flow, and currency exchange. The Global Beta Lactam & Beta Lactamase Inhibitors Market report delivers the high inflation expectation considering the related impact from cost-push and demand-pull inflation.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make better decisions. In this report, the years 2018 and 2021 are considered as historical years, 2022 as the base year, 2023 as the estimated year, and years from 2024 to 2030 are considered as the forecast period.

Market Segmentation & Coverage:

The report on the Global Beta Lactam & Beta Lactamase Inhibitors Market identifies key attributes about the customer to define the potential market and identify different needs across the industry. Understanding the potential customer group's economies and geographies can help gain business acumen for better strategic decision-making. The market coverage across different industry verticals reveals the hidden truth about the players' strategies in different verticals and helps the organization decide target audience. This report gives you the composite view of sub-markets coupled with comprehensive industry coverage and provides you with the right way of accounting factors such as norms & regulations, culture, to make right coverage strategy for the market plan. This research report categorizes the Global Beta Lactam & Beta Lactamase Inhibitors Market in order to forecast the revenues and analyze the trends in each of the following sub-markets:
  • Based on Drug Class, the market is studied across Carbapenem, Cephalosporins, Monobactam, and Penicillin.
  • Based on Disease, the market is studied across Blood Stream Infection, Complicated Intra-Abdominal Infections (cIAI), Complicated Urinary Tract Infection (cUTI), Nosocomial Pneumonia, Respiratory Infection, Skin Infection, and Urinary Tract Infection (excluding cUTI).
  • Based on Route of Administration, the market is studied across Intravenous and Oral.
  • Based on Region, the market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes vendors in the Global Beta Lactam & Beta Lactamase Inhibitors Market. based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) and placed into four quadrants (F: Forefront, P: Pathfinder, N: Niche, and V: Vital). The Global Beta Lactam & Beta Lactamase Inhibitors Market FPNV Positioning Matrix representation/visualization further aids businesses in better decision-making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market, providing the idea of revenue generation into the overall market compared to other vendors in the space. This provides insights on vendors performance in terms of revenue generation and customer base compared to others. The Global Beta Lactam & Beta Lactamase Inhibitors Market Share Analysis offers an idea of the size and competitiveness of the vendors for the base year. The outcome reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:

The Competitive Scenario provides an outlook analysis of the various strategies for business growth adopted by the vendors. The news in this section covers valuable insights at various stages while keeping up with the business and engaging stakeholders in the economic debate. The Global Beta Lactam & Beta Lactamase Inhibitors Market Competitive Scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected helps vendors understand the gaps in the marketplace and competitor’s strengths and weaknesses, providing insights to enhance products and services.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Beta Lactam & Beta Lactamase Inhibitors Market, including Allergan PLC by AbbVie Inc., Aurobindo Pharma Limited, Centrient Pharmaceuticals Netherlands B.V., GlaxoSmithKline PLC, Merck KGaA, Mylan N.V., Novartis AG, Pfizer Inc., Sumitomo Pharma Co., Ltd., and Venatorx Pharmaceuticals, Inc..

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation
5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Beta Lactam & Beta Lactamase Inhibitors Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Beta Lactam & Beta Lactamase Inhibitors Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Beta Lactam & Beta Lactamase Inhibitors Market?
4. What is the competitive strategic window for opportunities in the Global Beta Lactam & Beta Lactamase Inhibitors Market?
5. What are the technology trends and regulatory frameworks in the Global Beta Lactam & Beta Lactamase Inhibitors Market?
6. What is the market share of the leading vendors in the Global Beta Lactam & Beta Lactamase Inhibitors Market?
7. What modes and strategic moves are considered suitable for entering the Global Beta Lactam & Beta Lactamase Inhibitors Market?
Frequently Asked Questions about the Global Beta Lactam & Beta Lactamase Inhibitors Market

What is the estimated value of the Global Beta Lactam & Beta Lactamase Inhibitors Market?

The Global Beta Lactam & Beta Lactamase Inhibitors Market was estimated to be valued at $32.99 Billion in 2022.

What is the growth rate of the Global Beta Lactam & Beta Lactamase Inhibitors Market?

The growth rate of the Global Beta Lactam & Beta Lactamase Inhibitors Market is 10.5%, with an estimated value of $73.47 Billion by 2030.

What is the forecasted size of the Global Beta Lactam & Beta Lactamase Inhibitors Market?

The Global Beta Lactam & Beta Lactamase Inhibitors Market is estimated to be worth $73.47 Billion by 2030.

Who are the key companies in the Global Beta Lactam & Beta Lactamase Inhibitors Market?

Key companies in the Global Beta Lactam & Beta Lactamase Inhibitors Market include Allergan PLC by AbbVie Inc., Aurobindo Pharma Limited, Centrient Pharmaceuticals Netherlands B.V., GlaxoSmithKline PLC, Merck KGaA, Mylan N.V., Novartis AG, Pfizer Inc. and Venatorx Pharmaceuticals, Inc..

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing incidents of infectious diseases
5.1.1.2. Growing demand for over-the-counter drugs
5.1.1.3. Government initiatives to improve supply chain
5.1.2. Restraints
5.1.2.1. High cost of raw materials
5.1.3. Opportunities
5.1.3.1. Technological advances in beta lactam & beta lactamase inhibitor combinations
5.1.3.2. Increasing investments in pharmaceutical research
5.1.4. Challenges
5.1.4.1. Production complexities associated with beta lactam & beta lactamase inhibitors
5.2. Cumulative Impact of COVID-19
5.3. Cumulative Impact of Russia-Ukraine Conflict
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Threat of Substitutes
5.5.4. Threat of Substitutes
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
5.8. Client Customization

6. Beta Lactam & Beta Lactamase Inhibitors Market, by Drug Class
6.1. Introduction
6.2. Carbapenem
6.3. Cephalosporins
6.4. Monobactam
6.5. Penicillin

7. Beta Lactam & Beta Lactamase Inhibitors Market, by Disease
7.1. Introduction
7.2. Blood Stream Infection
7.3. Complicated Intra-Abdominal Infections (cIAI)
7.4. Complicated Urinary Tract Infection (cUTI)
7.5. Nosocomial Pneumonia
7.6. Respiratory Infection
7.7. Skin Infection
7.8. Urinary Tract Infection (excluding cUTI)

8. Beta Lactam & Beta Lactamase Inhibitors Market, by Route of Administration
8.1. Introduction
8.2. Intravenous
8.3. Oral

9. Americas Beta Lactam & Beta Lactamase Inhibitors Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Beta Lactam & Beta Lactamase Inhibitors Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa Beta Lactam & Beta Lactamase Inhibitors Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis, By Key Player
12.3. Market Share Analysis, By Key Player
12.4. Product Portfolio Analysis, By Key Player
12.5. Competitive Scenario
12.5.1. Merger & Acquisition
12.5.2. Agreement, Collaboration, & Partnership
12.5.3. New Product Launch & Enhancement
12.5.4. Investment & Funding
12.5.5. Award, Recognition, & Expansion

13. Company Usability Profiles
13.1. Allergan PLC by AbbVie Inc.
13.2. Aurobindo Pharma Limited
13.3. Centrient Pharmaceuticals Netherlands B.V.
13.4. GlaxoSmithKline PLC
13.5. Merck KGaA
13.6. Mylan N.V.
13.7. Novartis AG
13.8. Pfizer Inc.
13.9. Sumitomo Pharma Co., Ltd.
13.10. Venatorx Pharmaceuticals, Inc.

14. Appendix
14.1. Discussion Guide
14.2. License & Pricing


List of Figures
FIGURE 1. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET: RESEARCH PROCESS
FIGURE 2. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, 2022 VS 2030
FIGURE 3. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY REGION, 2022 VS 2030 (%)
FIGURE 5. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY REGION, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET COMPETITIVE STRATEGIC WINDOW, BY REGION, 2030
FIGURE 7. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 8. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2030
FIGURE 10. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET DYNAMICS
FIGURE 11. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET PORTER’S FIVE FORCES ANALYSIS
FIGURE 12. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2022 VS 2030 (%)
FIGURE 13. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 14. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET COMPETITIVE STRATEGIC WINDOW, BY DRUG CLASS, 2030
FIGURE 15. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CARBAPENEM, 2018-2030 (USD MILLION)
FIGURE 16. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CEPHALOSPORINS, 2018-2030 (USD MILLION)
FIGURE 17. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY MONOBACTAM, 2018-2030 (USD MILLION)
FIGURE 18. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PENICILLIN, 2018-2030 (USD MILLION)
FIGURE 19. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2022 VS 2030 (%)
FIGURE 20. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 21. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET COMPETITIVE STRATEGIC WINDOW, BY DISEASE, 2030
FIGURE 22. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY BLOOD STREAM INFECTION, 2018-2030 (USD MILLION)
FIGURE 23. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY COMPLICATED INTRA-ABDOMINAL INFECTIONS (CIAI), 2018-2030 (USD MILLION)
FIGURE 24. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY COMPLICATED URINARY TRACT INFECTION (CUTI), 2018-2030 (USD MILLION)
FIGURE 25. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY NOSOCOMIAL PNEUMONIA, 2018-2030 (USD MILLION)
FIGURE 26. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY RESPIRATORY INFECTION, 2018-2030 (USD MILLION)
FIGURE 27. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY SKIN INFECTION, 2018-2030 (USD MILLION)
FIGURE 28. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY URINARY TRACT INFECTION (EXCLUDING CUTI), 2018-2030 (USD MILLION)
FIGURE 29. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2022 VS 2030 (%)
FIGURE 30. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 31. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET COMPETITIVE STRATEGIC WINDOW, BY ROUTE OF ADMINISTRATION, 2030
FIGURE 32. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
FIGURE 33. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
FIGURE 34. AMERICAS BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 35. AMERICAS BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 36. AMERICAS BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 37. AMERICAS BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2030
FIGURE 38. ARGENTINA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 39. BRAZIL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 40. CANADA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 41. MEXICO BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 42. UNITED STATES BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 43. UNITED STATES BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY STATE, 2022 VS 2030 (%)
FIGURE 44. UNITED STATES BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 45. UNITED STATES BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET COMPETITIVE STRATEGIC WINDOW, BY STATE, 2030
FIGURE 46. ASIA-PACIFIC BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 47. ASIA-PACIFIC BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 48. ASIA-PACIFIC BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 49. ASIA-PACIFIC BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2030
FIGURE 50. AUSTRALIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 51. CHINA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 52. INDIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 53. INDONESIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 54. JAPAN BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 55. MALAYSIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 56. PHILIPPINES BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 57. SINGAPORE BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 58. SOUTH KOREA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 59. TAIWAN BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 60. THAILAND BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 61. VIETNAM BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 62. EUROPE, MIDDLE EAST & AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 63. EUROPE, MIDDLE EAST & AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 64. EUROPE, MIDDLE EAST & AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 65. EUROPE, MIDDLE EAST & AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2030
FIGURE 66. DENMARK BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 67. EGYPT BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 68. FINLAND BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 69. FRANCE BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 70. GERMANY BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 71. ISRAEL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 72. ITALY BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 73. NETHERLANDS BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 74. NIGERIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 75. NORWAY BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 76. POLAND BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 77. QATAR BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 78. RUSSIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 79. SAUDI ARABIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 80. SOUTH AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 81. SPAIN BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 82. SWEDEN BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 83. SWITZERLAND BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 84. TURKEY BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 85. UNITED ARAB EMIRATES BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 86. UNITED KINGDOM BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 87. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET: FPNV POSITIONING MATRIX, 2022
FIGURE 88. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SHARE, BY KEY PLAYER, 2022
FIGURE 89. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET COMPETITIVE SCENARIO, BY KEY TYPE, 2022


List of Tables
TABLE 1. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
TABLE 3. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CARBAPENEM, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CARBAPENEM, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CARBAPENEM, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CEPHALOSPORINS, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CEPHALOSPORINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CEPHALOSPORINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY MONOBACTAM, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY MONOBACTAM, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY MONOBACTAM, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PENICILLIN, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PENICILLIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PENICILLIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY BLOOD STREAM INFECTION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY BLOOD STREAM INFECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY BLOOD STREAM INFECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY COMPLICATED INTRA-ABDOMINAL INFECTIONS (CIAI), 2018-2030 (USD MILLION)
TABLE 24. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY COMPLICATED INTRA-ABDOMINAL INFECTIONS (CIAI), BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY COMPLICATED INTRA-ABDOMINAL INFECTIONS (CIAI), BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY COMPLICATED URINARY TRACT INFECTION (CUTI), 2018-2030 (USD MILLION)
TABLE 27. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY COMPLICATED URINARY TRACT INFECTION (CUTI), BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY COMPLICATED URINARY TRACT INFECTION (CUTI), BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY NOSOCOMIAL PNEUMONIA, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY NOSOCOMIAL PNEUMONIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY NOSOCOMIAL PNEUMONIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY RESPIRATORY INFECTION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY RESPIRATORY INFECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY RESPIRATORY INFECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY SKIN INFECTION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY SKIN INFECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY SKIN INFECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY URINARY TRACT INFECTION (EXCLUDING CUTI), 2018-2030 (USD MILLION)
TABLE 39. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY URINARY TRACT INFECTION (EXCLUDING CUTI), BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY URINARY TRACT INFECTION (EXCLUDING CUTI), BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 53. ARGENTINA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 54. ARGENTINA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 55. ARGENTINA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 56. ARGENTINA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 57. BRAZIL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 58. BRAZIL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 59. BRAZIL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 60. BRAZIL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 61. CANADA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 62. CANADA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 63. CANADA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 64. CANADA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 65. MEXICO BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 66. MEXICO BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 67. MEXICO BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 68. MEXICO BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 69. UNITED STATES BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 70. UNITED STATES BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 71. UNITED STATES BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 72. UNITED STATES BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 73. UNITED STATES BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 74. ASIA-PACIFIC BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 75. ASIA-PACIFIC BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 76. ASIA-PACIFIC BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 77. ASIA-PACIFIC BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 78. ASIA-PACIFIC BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 79. AUSTRALIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 80. AUSTRALIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 81. AUSTRALIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 82. AUSTRALIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 83. CHINA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 84. CHINA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 85. CHINA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 86. CHINA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 87. INDIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 88. INDIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 89. INDIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 90. INDIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 91. INDONESIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 92. INDONESIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 93. INDONESIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 94. INDONESIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 95. JAPAN BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 96. JAPAN BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 97. JAPAN BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 98. JAPAN BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 99. MALAYSIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 100. MALAYSIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 101. MALAYSIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 102. MALAYSIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 103. PHILIPPINES BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 104. PHILIPPINES BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 105. PHILIPPINES BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 106. PHILIPPINES BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 107. SINGAPORE BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 108. SINGAPORE BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 109. SINGAPORE BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 110. SINGAPORE BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 111. SOUTH KOREA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 112. SOUTH KOREA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 113. SOUTH KOREA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 114. SOUTH KOREA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 115. TAIWAN BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 116. TAIWAN BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 117. TAIWAN BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 118. TAIWAN BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 119. THAILAND BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 120. THAILAND BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 121. THAILAND BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 122. THAILAND BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 123. VIETNAM BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 124. VIETNAM BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 125. VIETNAM BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 126. VIETNAM BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 127. EUROPE, MIDDLE EAST & AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 128. EUROPE, MIDDLE EAST & AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 129. EUROPE, MIDDLE EAST & AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 130. EUROPE, MIDDLE EAST & AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 131. EUROPE, MIDDLE EAST & AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 132. DENMARK BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 133. DENMARK BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 134. DENMARK BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 135. DENMARK BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 136. EGYPT BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 137. EGYPT BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 138. EGYPT BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 139. EGYPT BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 140. FINLAND BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 141. FINLAND BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 142. FINLAND BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 143. FINLAND BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 144. FRANCE BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 145. FRANCE BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 146. FRANCE BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 147. FRANCE BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 148. GERMANY BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 149. GERMANY BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 150. GERMANY BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 151. GERMANY BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 152. ISRAEL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 153. ISRAEL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 154. ISRAEL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 155. ISRAEL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 156. ITALY BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 157. ITALY BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 158. ITALY BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 159. ITALY BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 160. NETHERLANDS BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 161. NETHERLANDS BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 162. NETHERLANDS BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 163. NETHERLANDS BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 164. NIGERIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 165. NIGERIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 166. NIGERIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 167. NIGERIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 168. NORWAY BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 169. NORWAY BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 170. NORWAY BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 171. NORWAY BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 172. POLAND BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 173. POLAND BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 174. POLAND BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 175. POLAND BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 176. QATAR BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 177. QATAR BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 178. QATAR BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 179. QATAR BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 180. RUSSIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 181. RUSSIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 182. RUSSIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 183. RUSSIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 184. SAUDI ARABIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 185. SAUDI ARABIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 186. SAUDI ARABIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 187. SAUDI ARABIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 188. SOUTH AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 189. SOUTH AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 190. SOUTH AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 191. SOUTH AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 192. SPAIN BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 193. SPAIN BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 194. SPAIN BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 195. SPAIN BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 196. SWEDEN BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 197. SWEDEN BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 198. SWEDEN BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 199. SWEDEN BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 200. SWITZERLAND BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 201. SWITZERLAND BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 202. SWITZERLAND BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 203. SWITZERLAND BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 204. TURKEY BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 205. TURKEY BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 206. TURKEY BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 207. TURKEY BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 208. UNITED ARAB EMIRATES BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 209. UNITED ARAB EMIRATES BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 210. UNITED ARAB EMIRATES BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 211. UNITED ARAB EMIRATES BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 212. UNITED KINGDOM BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 213. UNITED KINGDOM BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 214. UNITED KINGDOM BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 215. UNITED KINGDOM BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 216. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET: FPNV POSITIONING MATRIX - SCORES, 2022
TABLE 217. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET: FPNV POSITIONING MATRIX - BUSINESS STRATEGY, 2022
TABLE 218. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET: FPNV POSITIONING MATRIX - PRODUCT SATISFACTION, 2022
TABLE 219. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET RANKING, BY KEY PLAYER, 2022
TABLE 220. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SHARE, BY KEY PLAYER, 2022
TABLE 221. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET PRODUCT PORTFOLIO ANALYSIS, BY KEY PLAYER, 2022
TABLE 222. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET MERGER & ACQUISITION
TABLE 223. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 224. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 225. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET INVESTMENT & FUNDING
TABLE 226. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET AWARD, RECOGNITION, & EXPANSION
TABLE 227. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET: LICENSE & PRICING

Companies Mentioned

  • Allergan PLC by AbbVie Inc.
  • Aurobindo Pharma Limited
  • Centrient Pharmaceuticals Netherlands B.V.
  • GlaxoSmithKline PLC
  • Merck KGaA
  • Mylan N.V.
  • Novartis AG
  • Pfizer Inc.
  • Sumitomo Pharma Co., Ltd.
  • Venatorx Pharmaceuticals, Inc.

Methodology

Loading
LOADING...